Abstracts tagged "Disease Activity"

Abstract Number: 1462 • 2018 ACR/ARHP Annual Meeting
Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness
Dana Orange¹, Caroline Jiang¹, Edward F. DiCarlo², Tania Pannellini³, Laura T. Donlin⁴, Serene Z. Mirza⁵, Mark P. Figgie⁶, Vivian P. Bykerk⁷, Ana-Maria Orbai⁸, Sarah Mackie⁹ and Susan M. Goodman³, ¹Rockefeller University, New York, NY, ²Laboratory Medicine, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Surgery, Hospital for Special Surgery, New York, NY, ⁷Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Stiffness is a hallmark of RA, but little is known about the etiology. We investigated stiffness association with RA disease activity and determined whether…
Abstract Number: 1675 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Meenakshi Jolly¹, Hervé Devilliers², Iñigo Rúa-Figueroa³, Desiree R Azizoddin⁴, Raúl Menor Almagro⁵, Francisco Javier López Longo⁶, Juan Gabriel Ovalles-Bonilla⁷, Alejandro Olivé-Marques⁸, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernandez-Nebro¹⁰, Jaime Calvo-Alen¹¹, Txaro García de Vicuña-Pinedo¹², Eva G Tomero-Muriel¹³, Esther Uriarte Isacelaya¹⁴, Angela Pecondon-Español¹⁵, Mercedes Freire-González¹⁶, Ricardo Blanco¹⁷, Marian Gantes Mora¹⁸, Monica Ibanez Barcelo¹⁹, Carlos Alberto Montilla-Morales²⁰, José José C Rosas-Gómez de Salazar²¹, Jesús García-Villanueva²², Paloma Vela-Casasempere²³, María E Ruiz-Lucea²⁴, Francisco J Toyos-Sáenz-de-Miera²⁵, José Hernández Beiraín²⁶, Elvira Diez Alvarez²⁷, Gema Bonilla-Hernán²⁸, Javier Narváez-García²⁹, José Andréu-Sánchez³⁰, Mireia Moreno-Martínez-Losa³¹, Ana Sánchez Atrio³², Maria Loreto Horcada³³, Tatiana Cobo-Ibáñez³⁴, Carlos Marras Fernandez-Cid³⁵, Tomas Ramón Vazquez Rodriguez³⁶, Eva Salgado-Pérez³⁷, Vicente Torrente³⁸, Juan Alegre-Sancho³⁹, Coral Mouriño-Rodriguez⁴⁰, Joel A. Block¹ and JM Pego-Reigosa⁴¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²de médecine Interne, Hôpital Universitaire Dijon, Dijon, France, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez, Spain, ⁶Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ¹⁵Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹H. Son Llatzer, Palma de Mallorca, Spain, ²⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²²HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²³Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁴Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Complejo Asistencial Universitario de León, León, Spain, ²⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ³⁰HOSPITAL PUERTA DE HIERRO, Madrid, Spain, ³¹HOSPITAL PARC TAULÍ, Barcelona, Spain, ³²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³³Rheumatology, Hospital de Navarra, Pamplona, Spain, ³⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷COMPLEJO HOSPITALARIO DE OURENSE, Ourense, Spain, ³⁸Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁹HOSPITAL DR. PESET, València, Spain, ⁴⁰Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ⁴¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: Remission & Low Disease activity state (LDAS) are the two new health outcome measures developed with “treat to target” strategy in mind for Systemic…
Abstract Number: 2041 • 2018 ACR/ARHP Annual Meeting
Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis
Clémence Gorlier¹, Hafid Ait Oufella², Ludivine Laurans², Alexandra Rousseau³, Sophie Georgin-Lavialle⁴, Harry Sokol⁵, Francis Berenbaum¹, Simon Tabassome⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam¹, ¹AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ²Inserm U970, Paris Cardiovascular Research Center, Paris, France, ³AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB, Paris, France, ⁴AP-HP Tenon hospital, Sorbonne Université Paris, Paris, France, ⁵AP-HP Saint-Antoine hospital, Sorbonne Université Paris, France, Paris, France, ⁶AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB), Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France
Background/Purpose: Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a cell surface receptor expressed mainly on monocytes and neutrophils, known to amplify inflammatory response. We…
Abstract Number: 2489 • 2018 ACR/ARHP Annual Meeting
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Irini Genitsaridi^1,2, Irini Flouri³, Argyro Repa², Nestor Avgoustidis², Nikolaos Kougkas², Ioannis Papalopoulos², Styliani Polia², Konstantinos Marias¹, Dimitris Plexousakis⁴, George Bertsias² and Prodromos Sidiropoulos², ¹Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece, ²Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ³Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklio, Greece, ⁴Information Systems Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece
Background/Purpose: Registry data have shown that treatment with bDMARDs induces remission or LDA (RLDA) in up-to 50% of RA patients. Approximately 30-50% of patients have…
Abstract Number: 2835 • 2018 ACR/ARHP Annual Meeting
Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu¹, Ann Ranger², Normand Allaire², Patrick Cullen³ and Laurence S Magder⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Biogen Idec, Cambridge, MA, ³Biogen Idec, Cambridge, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided…
Abstract Number: 386 • 2018 ACR/ARHP Annual Meeting
Differences in Body Composition in Myositis Patients and Healthy Controls Are Associated with Disease Activity and Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Ondrej Marecek⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Katerina Kubinova^1,2, Martin Klein^1,2, Lucia Vernerova^1,2, Olga Ruzickova^1,6, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Herman F Mann^1,7, Jiri Vencovsky^1,8 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skeletal muscle, pulmonary and articular involvement in idiopathic inflammatory myopathies (IIM) limit the mobility/self-sufficiency of patients, and can have a negative impact on body…
Abstract Number: 822 • 2018 ACR/ARHP Annual Meeting
Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis
Andrea D. Gloor¹, Daniel Yerly², Jennifer L. Cullmann³, Sabine Adler¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Department of Biomedical Research, University of Bern, Bern, Switzerland, ³Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is an unmet need for tools to quantify local disease activity in TAK.Methods: Sera of 21 TAK patients, aged between 18 and 56…
Abstract Number: 1467 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Lucía González-Rodríguez¹, Valentina Calamia¹, Patricia Fernández², Cristina Ruiz-Romero³, Antonio Julià⁴, Antonio Fernández-Nebro⁵, Jesús Tornero⁶, Sara Marsal⁴ and Francisco J Blanco³, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ³Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Spain, ⁵UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Spain, ⁶Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Muhammad Mehmood Riaz^1,2, Liang SHEN³, Lay Kheng Teoh⁴, Rangi Kandane-Rathnayake⁵ and Aisha Lateef⁶, ¹Department of Medicine, National University Hospital, Singapore, Singapore, ²Department of Medicine, Aga Khan University, karachi, Pakistan, ³Biostatistics Unit, National University Health System, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore, ⁵School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…
Abstract Number: 2086 • 2018 ACR/ARHP Annual Meeting
4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
Yunjung Choi¹, Ji-hyun Jung², Eun-Kyeong Lee², Myeung Su Lee³, Changhoon Lee⁴ and Wan-Hee Yoo⁵, ¹Division of Rheumatology, Department of Internal Medicine, Research Institute of Clinical Medicine of chonbuk national university-Biomedical Research Institute of chonbuk national university hospital, jeonju, Korea, Republic of (South), ²Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea, Republic of (South), ³Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Research Institute of Clinical Medicine of chonbuk national university-Biomedical Research Institute of chonbuk national university hospital, Jeonju, Korea, Republic of (South)
Background/Purpose: The purpose of the present study was to investigate whether ER stress inhibition by 4-phenylbutyric acid (4-PBA) ameliorates lupus manifestations in an experimental lupus…
Abstract Number: 2491 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Jing Yang¹, Hua Wei², Jianlin Huang³, Wenqiang Fan⁴, Hongzhi Wang⁵, Yongfu Wang⁶, Rong Mu⁷, Chun Li⁸, Jinmei Zou¹, Yu Zhang¹, Bin Wu⁹, Jianling Dong¹, Xiaofei Shi¹⁰, Xinwang Duan¹¹, Jianhong Wu¹², Fang He¹³, Hong Liu¹, Zhijun Li¹⁴, Guosheng Wang¹⁵, Shengguang Li¹⁶, Bei Wang¹⁷, Yanjie Hao¹⁸, Huiqiong Zhou¹⁹, Haili shen²⁰, Yang Cui²¹, Wenhui Huang²², Qing-chun Huang²³, Hui Xiao²⁴, Yuhua Jia²⁴, Fei Xiao²⁴ and Feng-Chun Zhang²⁵, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵The First Hospital of Jiaxing, Jiaxing, China, ⁶The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁷Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁸Peking University People's Hospital, Beijing, China, ⁹Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹¹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹²Dazhou Central Hospital, Dazhou, China, ¹³Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁵Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹⁶Peking University International Hospital, Beijing, China, ¹⁷Beijing Hospital of Traditional Chinese Medicine (TCM), Beijing, China, ¹⁸The First Affiliated Hospital of Beijing University, Beijing, China, ¹⁹The First Affiliated Hospital of PLA General Hospital, Beijing, China, ²⁰Department of Rheumatology and Immunology, Second Hospital of Lanzhou University, lanzhou, China, ²¹Guangdong General Hospital, Guangzhou, China, ²²The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ²³Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: T2T, achieving a DAS28 score lower than 3.2 is the main management strategy recommended by ACR and EULAR. HAQ is the most widely used…
Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Huifeng Yun¹, Lang Chen¹, Fenglong Xie¹, Himanshu Patel², Natalie Boytsov², Xiang Zhang² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting
ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Emmanouil Rampakakis², Mohammad Movahedi³, Angela Cesta³, John S. Sampalis⁴ and Claire Bombardier³, ¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada
ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…
Abstract Number: 870 • 2017 ACR/ARHP Annual Meeting
Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Akiyuki Kotoku⁴, Atsuma Nishiwaki⁵, Kaita Sugiyama⁶, Noboru Kitamura⁵ and Masami Takei⁵, ¹Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ⁴Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Cardiac involvements cause of morbidity and mortality globally in rheumatoid arthritis (RA). Myocardial disease is typically clinically silent, only manifesting as myocardial dysfunction after…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].